Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05226780 · ClinicalTrials.gov registry record · Phase 2
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
A Phase 2 study of SCN8A Developmental and Epileptic Encephalopathy Syndrome, sponsored by Neurocrine Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 4
- Study locations
NCT05226780 is a Phase 2 study of SCN8A Developmental and Epileptic Encephalopathy Syndrome that is active but no longer recruiting, run by Neurocrine Biosciences. The registered enrollment target is 8 participants. The trial reports 4 study locations across 4 states.
The verdict
NCT05226780, a Phase 2 study of SCN8A Developmental and Epileptic Encephalopathy Syndrome, is active but no longer recruiting, sponsored by Neurocrine Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 4
- Study locations
Study Summary
Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
Conditions Studied
Interventions
- DRUG NBI-921352
Study Locations (4)
California
- UCSF Medical Center - San Francisco
District of Columbia
- Children's National Hospital - Washington D.C.
New York
- University of Rochester - Rochester
Texas
- Cook Children's Medical Center - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05226780
The ClinicalTrials.gov registry entry for NCT05226780 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neurocrine Biosciences, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SCN8A Developmental and Epileptic Encephalopathy Syndrome appearing as the primary indexed condition, and to 1 intervention - of which NBI-921352 is the first listed.
NCT05226780 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, District of Columbia, New York.
Frequently Asked Questions
What is clinical trial NCT05226780 about?
NCT05226780 is a clinical study titled "Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE". Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
What is the current status of trial NCT05226780?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2022-07-12. Estimated completion is 2026-03.
What conditions does trial NCT05226780 study?
This clinical trial studies the following conditions: SCN8A Developmental and Epileptic Encephalopathy Syndrome.
What interventions are being tested in trial NCT05226780?
The interventions under investigation include: NBI-921352 (DRUG).
Who is sponsoring clinical trial NCT05226780?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05226780 being conducted?
This trial has 4 study locations across California, District of Columbia, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.